Compare Merck & Co., Inc. (MRK) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Nokia Corp — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Nokia Corp trades at $10.93 (market cap $56.70B). The key difference: Merck & Co., Inc. is far larger — about 5.4× Nokia Corp's market cap, and Merck & Co., Inc. pays the higher dividend (2.73%). Which is the better fit depends on your goals.
| MRK | NOK | |
|---|---|---|
Market Cap | $307.25B | $56.70B |
Sector | Health | Technology |
52-Week High | $129.52 | $16.83 |
52-Week Low | $77.60 | $4.05 |
Enterprise Value | $350.66B | $53.51B |
Dividend Yield | 2.73% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Nokia (NOK) trades at $10.65, up 5.24% on the day, with a bullish analyst consensus price target of $18.00 representing significant upside. Recent earnings show mixed results with a Q1 2026 miss but Q3 and Q4 2025 beats. The company is pivoting toward AI and 5G infrastructure, evidenced by new partnerships and strong revenue growth in these segments. Technical indicators are mixed, with oscillators bullish but moving averages bearish, suggesting near-term consolidation.
The outlook is cautiously optimistic, driven by AI networking demand and strategic deals, but risks include intense competition and execution challenges. Valuation appears stretched with a P/E of 63.22, requiring sustained earnings growth to justify current levels. The stock offers potential for long-term growth if AI initiatives deliver, but near-term volatility is likely.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
